ARS Pharmaceuticals, Inc.
SPRYDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How SPRY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARS-1 | Phase 2 | Asthma | - | - |
0.5 mg epinephrine | Phase 2 | Urticaria Chronic | - | - |
Frequently asked questions
What is in ARS Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ARS Pharmaceuticals, Inc.'s (SPRY) pipeline across Phase 2. Its lead program is ARS-1 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ARS Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ARS Pharmaceuticals, Inc. (SPRY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SPRY biotech catalysts?→
Add SPRY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ARS Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.